Keppra approved from 1 month

Keppra (levetiracetam) has been approved for adjunctive treatment of partial-onset seizures with or without secondary generalisation in children from 1 month of age. It was previously licensed for this indication only in children over 6 months.

The starting dose in children aged 1-6 months is 7mg/kg oral solution twice daily.

View Keppra drug record

Further information: UCB


To sign up for the MIMS monthly news update, register at www.mims.co.uk/bulletins.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

SGLT2 inhibitors summarised in new MIMS table

SGLT2 inhibitors summarised in new MIMS table

Prescribers can quickly compare key features and benefits...

Proposed withdrawal of bipolar disorder treatment revoked

Proposed withdrawal of bipolar disorder treatment revoked

The manufacturer of first-line bipolar disorder treatment...